
Jonathan Gloth, MD, explains how MK-8748's dual Tie2 agonist/VEGF inhibitor mechanism differs from VEGF blockade alone, and what distinguishes an unstable vessel from a stabilized one in wet AMD.

Jonathan Gloth, MD is a board-certified ophthalmologist and retinal surgery specialist practicing at InVision Eye Care. He specializes in the treatment of age-related macular degeneration, diabetic retinopathy, retinal vascular occlusions, and uveitis.
Dr. Gloth was board-certified by the American Board of Ophthalmology in 2011. He is a fellow of the American Academy of Ophthalmology and a member of the American Society of Retina Specialists. Dr. Gloth’s work has been published in peer-reviewed journals and presented numerous times at national meetings.

Jonathan Gloth, MD, explains how MK-8748's dual Tie2 agonist/VEGF inhibitor mechanism differs from VEGF blockade alone, and what distinguishes an unstable vessel from a stabilized one in wet AMD.